Literature DB >> 34788196

Global meta-analysis on Babesia infections in human population: prevalence, distribution and species diversity.

Solomon Ngutor Karshima1, Magdalene Nguvan Karshima2, Musa Isiyaku Ahmed3.   

Abstract

Human babesiosis is an emerging tick-borne protozoan zoonosis caused by parasites of the genus Babesia and transmitted by ixodid ticks. It was thought to be a public health problem mainly for the immunocompromised, however the increasing numbers of documented cases among immunocompetent individuals is a call for concern. In this systematic review and meta-analysis, we reported from 22 countries and 69 studies, an overall pooled estimate (PE) of 2.23% (95% CI: 1.46-3.39) for Babesia infections in humans. PEs for all sub-groups varied significantly (p < 0.05) with a continental range of 1.54% (95% CI: 0.89-2.65) in North America to 4.17% (95% CI: 2.11-8.06) in Europe. PEs for country income levels, methods of diagnosis, study period, sample sizes, Babesia species and targeted population ranged between 0.43% (95% CI: 0.41-0.44) and 7.41% (95% CI: 0.53-54.48). Babesia microti recorded the widest geographic distribution and was the predominant specie reported in North America while B. divergens was predominantly reported in Europe. Eight Babesia species; B. bigemina, B. bovis, B. crassa-like, B. divergens, B. duncani, B. microti, B. odocoilei and B. venatorum were reported in humans from different parts of the world with the highest prevalence in Europe, lower middle income countries and among individuals with history of tick bite and other tick-borne diseases. To control the increasing trend of this emerging public health threat, tick control in human settlements, the use of protective clothing by occupationally exposed people and the screening of transfusion blood in endemic countries are recommended.Abbreviations AJOL: African Journals OnLine, CI: Confidence interval, CIL: Country income level, df: Degree of freedom, HIC: Higher-income countries, HQ: High quality, I2: Inverse variance index, IFAT: Indirect fluorescent antibody test, ITBTBD: Individuals with tick-bite and tick-borne diseases, JBI: Joanna Briggs Institute, LIC: Lower-income countries, LMIC: Lower middle-income countries, MQ: Medium quality, NA: Not applicable, N/America: North America, OEI: Occupational exposed individuals, OR: Odds ratio, PE: Pooled estimates, PCR: Polymerase chain reaction, Prev: Prevalence, PRISMA: Preferred Reporting System for Systematic Reviews and Meta-Analyses, Q: Cochran's heterogeneity statistic, QA: Quality assessment, Q-p: Cochran's p-value, qPCR: Quantitative polymerase chain reaction, S/America: South America, Seq: Sequencing, UMIC: Upper middle-income countries, USA: United States of America.

Entities:  

Keywords:  Geographic distribution; human babesiosis; prevalence; species diversity; zoonotic Babesia species

Mesh:

Year:  2021        PMID: 34788196      PMCID: PMC9132453          DOI: 10.1080/20477724.2021.1989185

Source DB:  PubMed          Journal:  Pathog Glob Health        ISSN: 2047-7724            Impact factor:   3.735


  120 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Serological survey in persons occupationally exposed to tick-borne pathogens in cases of co-infections with Borrelia burgdorferi, Anaplasma phagocytophilum, Bartonella spp. and Babesia microti.

Authors:  Jolanta Chmielewska-Badora; Anna Moniuszko; Wioletta Żukiewicz-Sobczak; Jacek Zwoliński; Jacek Piątek; Sławomir Pancewicz
Journal:  Ann Agric Environ Med       Date:  2012       Impact factor: 1.447

3.  Severe babesiosis caused by Babesia divergens in a host with intact spleen, Russia, 2018.

Authors:  Irina V Kukina; Olga P Zelya; Tatiana M Guzeeva; Ludmila S Karan; Irina A Perkovskaya; Nina I Tymoshenko; Marina V Guzeeva
Journal:  Ticks Tick Borne Dis       Date:  2019-07-16       Impact factor: 3.744

4.  First case of human babesiosis in Germany - Clinical presentation and molecular characterisation of the pathogen.

Authors:  Katja Häselbarth; Astrid M Tenter; Volker Brade; Gerhard Krieger; Klaus-Peter Hunfeld
Journal:  Int J Med Microbiol       Date:  2007-03-12       Impact factor: 3.473

5.  A cluster of transfusion-associated babesiosis cases traced to a single asymptomatic donor.

Authors:  J Dobroszycki; B L Herwaldt; F Boctor; J R Miller; J Linden; M L Eberhard; J J Yoon; N M Ali; H B Tanowitz; F Graham; L M Weiss; M Wittner
Journal:  JAMA       Date:  1999-03-10       Impact factor: 56.272

6.  Human babesiosis in Taiwan: asymptomatic infection with a Babesia microti-like organism in a Taiwanese woman.

Authors:  C M Shih; L P Liu; W C Chung; S J Ong; C C Wang
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

Review 7.  Babesia divergens, a bovine blood parasite of veterinary and zoonotic importance.

Authors:  Annetta Zintl; Grace Mulcahy; Helen E Skerrett; Stuart M Taylor; Jeremy S Gray
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

8.  A prospective evaluation of chronic Babesia microti infection in seroreactive blood donors.

Authors:  Evan M Bloch; Andrew E Levin; Phillip C Williamson; Sherri Cyrus; Beth H Shaz; Debra Kessler; Jed Gorlin; Roberta Bruhn; Tzong-Hae Lee; Leilani Montalvo; Hany Kamel; Michael P Busch
Journal:  Transfusion       Date:  2016-05-17       Impact factor: 3.157

9.  Human Babesiosis, Bolivia, 2013.

Authors:  Simona Gabrielli; Valentina Totino; Fabio Macchioni; Freddy Zuñiga; Patricia Rojas; Yuni Lara; Mimmo Roselli; Alessandro Bartoloni; Gabriella Cancrini
Journal:  Emerg Infect Dis       Date:  2016-08       Impact factor: 6.883

10.  Molecular characterization of a non-Babesia divergens organism causing zoonotic babesiosis in Europe.

Authors:  Barbara L Herwaldt; Simone Cacciò; Filippo Gherlinzoni; Horst Aspöck; Susan B Slemenda; PierPaolo Piccaluga; Giovanni Martinelli; Renate Edelhofer; Ursula Hollenstein; Giovanni Poletti; Silvio Pampiglione; Karin Löschenberger; Sante Tura; Norman J Pieniazek
Journal:  Emerg Infect Dis       Date:  2003-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.